AdJane Introduces Mucosal Immunity Booster for Next-Gen Respiratory Vaccines

AdJane Biosciences, a pioneering force in next-generation vaccine platforms, has announced an innovative approach to enhancing mucosal immunity, which could revolutionize respiratory vaccination strategies. This new initiative is detailed in their recently published technical white paper, titled "Boosting mRNA Mucosal Immunity and a Platform Beyond It." The report outlines the promising applications of their native outer membrane vesicle technology, known as Nm-nOMV.

The Role of Mucosal Immunity

Mucosal immunity is crucial in preventing respiratory pathogens, as they typically enter the body through mucosal surfaces. Current intramuscular vaccines provide robust systemic immunity but often see limited effectiveness at these mucosal entry points. Recent findings indicate that mucosal immune responses, particularly IgA antibodies, may play a significant role in reducing pathogen transmission where they first invade. This indicates a clear opportunity for improving current vaccination approaches and supporting public health goals aimed at lowering infection rates and disease severity.

Innovative Strategy

AdJane's strategy aims to leverage the existing systemic immunity generated by intramuscular vaccines, while also introducing an intranasal booster dose of their Nm-nOMV technology. This combination is designed to stimulate complementary mucosal immunity, fostering a potent barrier against respiratory infections. Anita Gashi, CEO of AdJane, emphasized the importance of building upon established vaccines: "Innovation in respiratory vaccines can stem from what already works. By adding an intranasal booster dose of Nm-nOMV to existing intramuscular vaccines, we aim to induce immunity right where infection starts."

Potential Applications and IP Portfolio

The robust applicability of the Nm-nOMV platform extends far beyond COVID-19. AdJane has developed an extensive intellectual property portfolio that covers platform technology, production processes, and mucosal delivery mechanisms aimed at multiple respiratory infections. They are also seeking patents for combinations of their OMV technology with mRNA vaccines.

Initial clinical data from a recently concluded Phase I trial backs the concept of a mucosal booster. Participants, who had previously received mRNA vaccines for COVID-19, showed favorable tolerance and significant nasal IgA responses post-intranasal administration of a Nm-nOMV vaccine expressing the SARS-CoV-2 Spike protein. These preliminary results support the hypothesis of a heterologous prime-boost strategy, although further studies will be necessary to explore the durability and clinical significance of these mucosal immune responses.

Broader Implications for Vaccine Development

As public health initiatives increasingly seek to combat infectious diseases through comprehensive vaccination strategies, AdJane's Nm-nOMV platform represents a forward-looking technological advancement. The potential to create a new generation of vaccines that effectively address not only systemic but also mucosal immunity could reshape the landscape of respiratory disease prevention. With plans to verify this dual immune approach in future clinical applications, the possibilities extend into various diseases like influenza, RSV, and even preparations for potential future pandemics.

For additional insights, the full white paper can be accessed at AdJane's official website.

About AdJane

AdJane Biosciences is at the forefront of clinical-stage innovations, focusing on developing scalable, multivalent vaccines that target both systemic and mucosal immunity. Their research is built on over 30 years of foundational knowledge in Dutch vaccine research and is clinically validated for safety and immunogenic response in mucosal tissues. With ongoing projects targeting diverse viral and bacterial indications, AdJane aims to validate and expand the utility of their vaccine platform.

For media inquiries or further information, please contact:
Anita Gashi, CEO, [email protected]
Jessica Hodgson, Media Contact, [email protected]